1. Home
  2. > Pharmaceutical
  3. > Therapy Market Trends
Factor XI inhibitors - Pipeline Insight, 2022

Factor XI inhibitors - Pipeline Insight, 2022

  • January 2022
  • 60 pages
  • ID: 6222939
  • Format: PDF
  • Delve Insight


Table of Contents

“Factor XI inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Factor XI inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Factor XI inhibitors Understanding

Factor XI inhibitors: Overview
Current anticoagulants target enzymes, including FXa or thrombin, in the common pathway of coagulation, but the intrinsic pathway at the level of FXI and FXII has attracted attention in recent years. The intrinsic pathway is activated when blood comes into contact with medical devices like stents, mechanical heart valves, or central venous catheters, but evidence also suggests that it plays a role in clot stabilization and growth, he explained, noting additional evidence of attenuation of thrombosis in mice deficient in FXI or FXII and in animals with FXI or FXII inhibitors. The initiators of the intrinsic pathway are naturally occurring polyphosphates that can activate FXI and FXII, promote platelet activation, and lead to thrombosis. Factor XI has emerged as a promising target for new anticoagulants, and several strategies for inhibiting the enzyme to reduce stroke, thromboembolism, and bleeding risk are under investigation.

"Factor XI inhibitors - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Factor XI inhibitors pipeline landscape is provided which includes the disease overview and Factor XI inhibitors treatment guidelines. The assessment part of the report embraces, in depth Factor XI inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Factor XI inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
? The companies and academics are working to assess challenges and seek opportunities that could influence Factor XI inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Factor XI inhibitors.

Factor XI inhibitors Emerging Drugs Chapters
This segment of the Factor XI inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Factor XI inhibitors Emerging Drugs
• IONIS FXI LRX: Ionis Pharmaceuticals
Fesomersen, formerly known as IONIS-FXI-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of Factor XI, a clotting factor produced in the liver that is an important component of the coagulation pathway. IONIS-FXI-LRx utilizes Ionis’ advanced LIgand Conjugated Antisense (LICA) technology platform and is designed to reduce the production of Factor XI. In May 2015, Ionis entered into an exclusive license agreement with Bayer to develop and commercialize Ionis’ programs targeting FXI for the treatment of clotting disorders. Under the agreement, Ionis has generated more than $185 million to date, including a $10 million milestone payment Ionis earned with Bayer’s continuation decision. It is currently being evaluated in Phase II stage of development for the treatment of Thrombosis.

• AB 023: Aronora, Inc.
AB023 (xisomab 3G3) is a recombinant factor XI (FXI) antibody that specifically inhibits contact activation of blood. AB023 is entirely unique in the growing armamentarium of FXI targeting drugs under development since it specifically inhibits FXI activation by factor XII (FXII) without inhibiting FXI feedback activation by thrombin. Since FXII deficiency in humans does not result in any known bleeding side-effects, as opposed to FXI deficiency (also known as hemophilia C), AB023 could be an exceptionally safe antithrombotic agent. As such, AB023 represents a fundamentally novel antithrombotic concept. AB023 is currently in the phase 2 clinical trial stage. It is being developed to prevent various thrombotic complications associated with chronic hemodialysis, as well as to limit blood clot formation on catheters and other intravascular, intracardiac or extracorporeal medical devices.
Further product details are provided in the report……..

Factor XI inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Factor XI inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
? Major Players in Factor XI inhibitors
There are approx. 8+ key companies which are developing the therapies for Factor XI inhibitors. The companies which have their Factor XI inhibitors drug candidates in the most advanced stage, i.e. phase II include Ionis Pharmaceuticals.
? Phases
This report covers around 8+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

? Route of Administration
Factor XI inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Intramuscular
? Molecule Type

Products have been categorized under various Molecule types such as
• Peptides
• Polymer
• Small molecule
? Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Factor XI inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Factor XI inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Factor XI inhibitors drugs.

Factor XI inhibitors Report Insights
• Factor XI inhibitors Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Factor XI inhibitors Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Factor XI inhibitors drugs?
• How many Factor XI inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Factor XI inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Factor XI inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Factor XI inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Addiction Disorders Drugs Market Research Report by Drug Type, Treatment, End-user, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • $ 3949
  • January 2023
  • 222 pages

Addiction Disorders Drugs Market Research Report by Drug Type (Alcohol, Marijuana, and Prescription & Over-the-Counter Medications), Treatment, End-user, Region - Cumulative Impact of COVID-19, Russia ...

  • World
  • Therapy
  • Marijuana
  • Industry analysis


Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on